This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Corcept Therapeutics (CORT) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Corcept Therapeutics (CORT) has been struggling lately, but the selling pressure may be coming to an end soon
Earnings Preview: Corcept Therapeutics (CORT) Q1 Earnings Expected to Decline
by Zacks Equity Research
Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Corcept (CORT) Down 11.1% Since Last Earnings Report?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept (CORT) Begins Adrenal Cancer Study on Relacorilant
by Zacks Equity Research
Corcept (CORT) commences phase Ib study on relacorilant in combination with Keytruda for treating patients with adrenal cancer with cortisol excess.
Corcept (CORT) Q4 Earnings In Line, Revenues Miss Estimates
by Zacks Equity Research
Corcept's (CORT) earnings meet estimates in the fourth quarter of 2020 while revenues miss the same.
AMRX or CORT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMRX vs. CORT: Which Stock Is the Better Value Option?
Corcept (CORT) Posts Preliminary '20 Results, Gives 2021 View
by Zacks Equity Research
Corcept (CORT) provides preliminary revenue figures for fourth-quarter and full-year 2020. The company also issues revenue guidance for 2021. Shares down in after-hours trading.
Why Corcept Therapeutics (CORT) Might Surprise This Earnings Season
by Zacks Equity Research
Corcept Therapeutics (CORT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Corcept (CORT) Up More Than 50% in Past 3 Months: Here's Why
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.
Why Is Corcept (CORT) Up 25.8% Since Last Earnings Report?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for November 5th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Corcept (CORT) Misses on Q3 Earnings, Tightens 2020 Sales View
by Zacks Equity Research
Corcept's (CORT) earnings and revenues fall shy of estimates in the third quarter of 2020. The company tapers its revenue guidance for the year. Shares fall in after-hours trading.
Corcept Therapeutics (CORT) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of -19.05% and -4.23%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Corcept's Lead Drug Korlym Aids Growth, Heavy Reliance a Woe
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug Korlym shows a steady progress. Other pipeline candidates are advancing as well. However, heavy dependence on Korlym for growth remains an overhang.
Why Is Corcept (CORT) Up 38.4% Since Last Earnings Report?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is the Options Market Predicting a Spike in Corcept Therapeutics (CORT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Corcept Therapeutics (CORT) stock based on the movements in the options market lately.
Corcept (CORT) Q2 Earnings Top Estimates, Revenues Miss Mark
by Zacks Equity Research
Corcept's (CORT) earnings trump estimates for the second quarter of 2020 while revenues fall shy of the same.
Corcept Begins Enrollment in Phase III Pancreatic Cancer Study
by Zacks Equity Research
Corcept (CORT) enrolls the first patient in the phase III RELIANT study on relacorilant in combination with Abraxane for treating metastatic pancreatic cancer.
Why Is Corcept (CORT) Up 8.2% Since Last Earnings Report?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Has Corcept Therapeutics (CORT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (CORT) Outperforming Other Medical Stocks This Year?
Corcept (CORT) Q1 Earnings Top Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Corcept's (CORT) earnings and revenues beat estimates in the first quarter of 2020. Solid adoption of the company's Cushing's syndrome drug, Korlym, drives sales.
New Strong Buy Stocks for May 5th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Corcept Therapeutics (CORT) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of 19.05% and 7.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Are You Looking for a Top Momentum Pick? Why Corcept Therapeutics (CORT) is a Great Choice
by Zacks Equity Research
Does Corcept Therapeutics (CORT) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Growth ETFs & Stocks Set to Flourish in Spring
by Sweta Killa
Given the recovering sentiments, investors should reposition their portfolio for more exposure to the growth space to obtain a nice momentum play.